Company intelligence / Profile preview

Ventus Medical

Ownership: Private
Employees: ~112
Development stage: Other

Overview

Ventus has advanced two lead programs from target screening to successful completion of Phase 1 trials in under five years. VENT‑02, an oral brain‑penetrant NLRP3 inhibitor, is in Phase 2 for Parkinson’s disease and entering additional trials for osteoarthritis. VENT‑03, a first-in-class cGAS inhibitor, will enter Phase 2 development for lupus and treatment-refractory rheumatoid arthritis. Multiple additional preclinical programs are ongoing. No pivotal data readouts yet reported as of June 2025.

Therapeutic areas: RheumatologyImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

No major pharma partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Ventus Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ventus Medical.

Explore the full profile